Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...